Documentos clave
AB5200
Anti-Potassium Channel GIRK2 Antibody
Chemicon®, from rabbit
Sinónimos:
G-protein Activated Inwardly Rectifying Potassium Channel
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Código UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
origen biológico
rabbit
Nivel de calidad
conjugado
unconjugated
forma del anticuerpo
affinity purified immunoglobulin
tipo de anticuerpo
primary antibodies
clon
polyclonal
purificado por
affinity chromatography
reactividad de especies
mouse, rat
fabricante / nombre comercial
Chemicon®
técnicas
immunohistochemistry: suitable
western blot: suitable
Nº de acceso NCBI
Nº de acceso UniProt
Condiciones de envío
wet ice
modificación del objetivo postraduccional
unmodified
Información sobre el gen
human ... KCNJ6(3763)
Inmunógeno
GST fusion protein from the C-terminal portion of mouse GIRK2 protein (amino acids 374-414) (Accession P48542).
Aplicación
Anti-Potassium Channel GIRK2 Antibody detects level of Potassium Channel GIRK2 & has been published & validated for use in IH & WB.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Ion Channels & Transporters
Ion Channels & Transporters
Western blot: 1:200 using ECL on rat brain membranes.
Immunohistochemistry on rat brain sections.
Dilutions should be made using a carrier protein such as BSA (1-3%)
Optimal working dilutions must be determined by the end user.
Immunohistochemistry on rat brain sections.
Dilutions should be made using a carrier protein such as BSA (1-3%)
Optimal working dilutions must be determined by the end user.
Acciones bioquímicas o fisiológicas
Recognizes a full length Kir3.2 (GIRK2, G-protein Activated Inwardly Rectifying Potassium Channel 2). Does not cross react with any other potassium channel antigens tested so far.
Forma física
Affinity purified immunoglobulin. Lyophilized from phosphate buffered saline, pH 7.4, containing 1% BSA, 5% sucrose as a stabilizer and 0.025% sodium azide as a preservative. Reconstitute with 200 μL of sterile deionized water. Centrifuge antibody preparation before use (10,000 xg for 5 min).
Nota de preparación
Maintain lyophilized material at -20°C for up to 12 months. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles
Nota de análisis
Control
CONTROL ANTIGEN: Included free of charge with the antibody is 120 μg of control antigen (lyophilized powder). The stock solution of the antigen can be made up using 100 μL of PBS. For positive control, in Western blot use 20 ng of protein per minigel lane. For negative control, preincubate 3 μg of fusion protein with 1 μg of antibody for one hour at room temperature. Optimal concentrations must be determined by the end user.
CONTROL ANTIGEN: Included free of charge with the antibody is 120 μg of control antigen (lyophilized powder). The stock solution of the antigen can be made up using 100 μL of PBS. For positive control, in Western blot use 20 ng of protein per minigel lane. For negative control, preincubate 3 μg of fusion protein with 1 μg of antibody for one hour at room temperature. Optimal concentrations must be determined by the end user.
Otras notas
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Información legal
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Cláusula de descargo de responsabilidad
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Frases de peligro
Consejos de prudencia
Clasificaciones de peligro
Aquatic Chronic 3
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 3
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Tammy Ryan et al.
Nature communications, 9(1), 817-817 (2018-02-28)
Neuronal loss in Parkinson's disease (PD) is associated with aberrant mitochondrial function and impaired proteostasis. Identifying the mechanisms that link these pathologies is critical to furthering our understanding of PD pathogenesis. Using human pluripotent stem cells (hPSCs) that allow comparison
Andrzej Swistowski et al.
Current protocols in stem cell biology, Chapter 2, Unit2D-Unit2D (2012-08-09)
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are potentially an unlimited cell source for cell replacement therapy and personalized medicine. Before hESC- and iPSC-based therapy can be moved from bench to bedside, however, it is essential
Andrzej Swistowski et al.
PloS one, 4(7), e6233-e6233 (2009-07-15)
Human embryonic stem cells (hESCs) may provide an invaluable resource for regenerative medicine. To move hESCs towards the clinic it is important that cells with therapeutic potential be reproducibly generated under completely defined conditions. Here we report a four-step scalable
Fahad Mubariz et al.
Frontiers in neuroscience, 17, 1152503-1152503 (2023-06-19)
Mutations in the GBA1 gene are the single most frequent genetic risk factor for Parkinson's disease (PD). Neurodegenerative changes in GBA1-associated PD have been linked to the defective lysosomal clearance of autophagic substrates and aggregate-prone proteins. To elucidate novel mechanisms
Adolfo López-Ornelas et al.
Cells, 12(23) (2023-12-09)
Human embryonic stem cells (hESCs) differentiate into specialized cells, including midbrain dopaminergic neurons (DANs), and Non-human primates (NHPs) injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine develop some alterations observed in Parkinson's disease (PD) patients. Here, we obtained well-characterized DANs from hESCs and transplanted them
Número de artículo de comercio global
| SKU | GTIN |
|---|---|
| AB5200-200UL | 04053252365843 |
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico